BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Although metformin monotherapy is not potent enough to conquer the development of CML, it enhanced the sensitivity of CML stem cells to imatinib, suggesting that synergistic use of imatinib with metformin, or ER stress inducer may provide an attractive approach to target BCR-ABL-independent mechanism of resistance.